ArticleJournal of gastrointestinal cancer2026
Microwave Ablation with or without TACE for Unresectable Large Hepatocellular Carcinoma: Impact of Tumor Burden Score on Efficacy.
Article in Journal of gastrointestinal cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundPatients with unresectable large HCC may be downstaged through TACE followed by MWA to achieve curative treatment. Controversially, for some patients, single MWA treatment may be sufficient. PURPOSE: This study aimed to evaluate the clinical outcomes of unresectable large HCC treated with transarterial chemoembolization (TACE) followed by microwave ablation (MWA) and compare them based on the tumor burden score (TBS), to provide a scientific basis for guiding treatment strategies.
methodsThis retrospective study included 294 patients with unresectable large HCC (449 tumors) treated with MWA between January 2010 and June 2023 at the General Hospital of the People's Liberation Army. Propensity score matching (PSM) was used to compare the TACE sequential MWA group (n = 103) with the single MWA group (n = 103). The primary endpoint was progression-free survival (PFS), with secondary endpoints including overall survival (OS) and occurrence of adverse events. Subgroup analyses were conducted by identifying TBS split points using the interaction cubic spline plot method.
resultsAmong the 294 patients, 76.5% were infected with hepatitis B virus (HBV), with a median age of 62.0 years and a mean maximum tumor diameter of 6.0 ± 1.1 cm. After PSM and with a median follow-up of 67.3 months, PFS was significantly worse in the single MWA group, while no significant difference was observed between the two treatments in OS or adverse events. Interaction cubic spline plot analysis indicated TBS split points of 5.7 and 7.5. A significant difference in PFS was observed when TBS was ≥ 5.7 (HR 1.91, 95% CI: 1.31-2.79, P = 0.001), and in OS when TBS was ≥ 7.5 (HR 2.75, 95% CI: 1.26-5.96, P = 0.011). Subgroup analysis revealed that the TACE sequential MWA group was more effective in controlling intrahepatic distant progression (HR 1.93, 95% CI: 1.30-2.87, P = 0.001).
conclusionTACE sequential MWA demonstrates superior efficacy compared to single MWA in patients with unresectable large HCC. However, when TBS is < 5.7, the two treatments may be comparable. For TBS ≥ 7.5, the combined treatment regimen should be prioritized.
Indexed as
Identifiers
42105132What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.